Jena / Frickenhausen, January 20th, 2016 – With the start of 2016 the distribution of the cervical cancer triage test GynTect® by Greiner Bio-One has started. For this purpose the internationally active company had closed a marketing and distribution partnership with oncgnostics GmbH, who has developed and produces the GynTect® test, prior to Medica 2015. The CE IVD mark which GynTect® received in October 2015 allows the utilization of the test in laboratories in whole Europe.
oncgnostics GmbH
The oncgnostics GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.
oncgnostics GmbH is working according to ISO 13485 standards in research, development, production and management.
Recent Posts
Contact
oncgnostics GmbH
Löbstedter Str. 41
07749 Jena
Germany
Phone: +49 (0)3641 5548500
Email: contact[at]oncgnostics.com
Internet: www.oncgnostics.com